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ABSTRACT
Introduction: Many studies have shown the association between PSA levels and the subse-
quent detection of prostate cancer. In the present trial, we have studied the relationship between
preoperative PSA levels and clinical outcome following radical prostatectomy in men with clinical
stage T1c.
Materials and Methods: 257 individuals with clinical stage T1c undergoing retropubic radi-
cal prostatectomy were selected in the period from 1991 to 2000. Following surgery, biochemical
recurrence-free survival curves were constructed according to PSA levels between 0-4; 4.1-10; 10.1-
20 and > 20 ng/mL.
Results: Of the total of 257 selected patients, 206 (80%) had Gleason scores from 2 to 6 and
51 (20%), presented Gleason scores 7 and 8, as defined by the pathological report from prostate
biopsy. There was no biochemical recurrence of disease when the PSA was lower than 4, regardless of
Gleason score. Biochemical recurrence-free survival according to PSA between 0-4; 4.1-10; 10.1-20
and > 20 was 100%, 87.6%, 79% and 68.8% for Gleason scores 2-6 and 100%; 79.4%; 40% and
100% for Gleason scores 7-8 respectively. When all individuals were grouped, regardless of their
Gleason scores, the probability of biochemical recurrence-free survival was 100%, 65.1%, 53.4%
and 72.2% according to PSA between 0-4; 4.1-10; 10.1-20 and > 20 ng/mL respectively.
Conclusion: Non-palpable prostate cancer presents higher chances of cure when the PSA is
inferior to 4 ng/mL.
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INTRODUCTION
Approximately 75% of men over 50 years old
are screened for prostate cancer (PCa) by testing the
prostate-specific antigen (PSA) (1); among those with
altered PSA, two thirds will be identified as having
PCa in stage T1c (2).
The indication for prostate biopsy when the
PSA exceeds 4 ng/mL should be assessed on an indi-
vidual basis, especially after recent data that showed
PCa in 23.9 to 26.9% of men with PSA between 2
and 4 ng/mL (3).
One concern about the indiscriminate use of
PSA is the diagnosis of insignificant tumors (4) and
the treatment of eventual tumors with low biological
aggressiveness. However, despite the initial identifi-
cation of PCa, 25 to 33% of individuals will die as a
consequence of the disease, though the majority is
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identified as T1c (2). The detection of early PCa in-
creases the chances of disease confined to the pros-
tate with lower risks of cancer recurrence following
the treatment (5), while some authors already believe
that the disease-related mortality is decreasing (6).
Due to the increasing debate concerning the
upper normal limits for PSA (7), this study aims to
assess preoperative PSA levels in individuals with
PCa clinical stage T1c undergoing radical prostatec-
tomy, as well as their postoperative outcome.
MATERIALS AND METHODS
The study assessed 257 men presenting a
clinical diagnosis of PCa stage T1c, with a mean age
of 63.2 ± 7.5 years (47 - 76). The mean preoperative
serum PSA was 8.7 ± 5.6 ng/mL (0.3-32.0), and the
mean postoperative follow-up time was 85.4 ± 6.1
months. These were retrospectively assessed.
The initial PSA was collected before pros-
tate biopsy. During staging, all patients underwent
anamnesis and physical examinations, alkaline phos-
phatase dosing, total and prostatic acid phosphatase,
pelvic computerized tomography and bone scintigra-
phy in order to rule out extraprostatic disease.
All participants underwent retropubic radi-
cal prostatectomies with bilateral pelvic iliac lym-
phadenectomy at our institution from March 1991 to
November 2000. The same surgeon (MS) performed
all surgical procedures and the same pathologist
(KRL) performed all pathological analyses.
Clinical staging was defined according to the
American Joint Committee on Cancer classification
(8), and histological grade according to Gleason score
(9).
For selection of this group, cases receiving
neoadjuvant or adjuvant hormone therapy (14 pa-
tients), as well as adjuvant radiotherapy (one patient),
were excluded.
Postoperatively, patients were assessed every
2 months during the first year, then every 6 months
for 5 years, and yearly from them on. During each
assessment, patients underwent digital rectal exami-
nations of the prostate cavity and analysis of serum
PSA. Imaging exams (chest radiography, bone scin-
tigraphy, abdominal tomography) were repeated ev-
ery year. Biochemical progression was defined as a
serum PSA higher than or equal to 0.4 ng/mL, a cut-
off value that was used by other authors as well (10).
The preoperative PSA was divided into cat-
egories of from 0 to 4 ng/mL, 4.1 to 10 ng/mL, 10.1
to 20 ng/mL and higher than 20 ng/mL. (The distri-
bution of patients according to preoperative PSA is
in Table-1). Initially, we divided the patients into 2
groups: low risk (Gleason scores 2-6) and high risk
(Gleason scores 7-10). Subsequently, we grouped all
individuals together to build the survival curve.
For the statistical analysis, we used an ap-
proach of survival analysis considering the biochemi-
cal recurrence of the disease as the event of interest,
defined by a PSA value higher than or equal to 0.4
ng/mL. For the disease-free survival curves, we used
the Kaplan-Meier method and the Breslow and Log-
Rank tests. A Cox regression model with proportional
risks was adjusted on the multivariate analysis. P val-
ues < 0.05 were considered to be statistically signifi-
cant.
RESULTS
Table-1 presents the distribution of 257 pa-
tients with clinical stage T1c showing the incidence
in relation to PSA values, where we can observe that
60% of them had PSA between 4.1 and 10.0.
Table-2 presents the 206 patients with clini-
cal stage T1c and Gleason scores of 2-6 (low risk) in
relation to PSA levels and events in relation to the
assessed PSA categories. In Figure-1, we can see that
PSA levels influenced the disease-free survival rates
of patients with clinical stage T1c (p = 0.008). We
can also observe that none of the patients with PSA
Table 1 – PSA distribution in patients with clinical stage
T1c.
PSA   N  (%)
0 - 4.0 017 (6.7)
4.1 - 10.0 155 (60.3)
10.1 - 20.0 067 (26)
> 20.0 018 (7)
Total 257 (100.0)
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between 0 and 4.0 presented a recurrence of disease
during the assessment period. When PSA levels os-
cillated between 4.1 and 20 ng/mL, they showed the
same prognosis (p = 0.102) in relation to the expect-
ancy of biochemical recurrence-free survival.
Table-3 represents the distribution of 51 pa-
tients with clinical stage T1c and Gleason scores of
7 and 8 according to PSA levels. It is important to
stress that there was no patient with a Gleason score
of 9 or 10. The survival probability curve for bio-
Table 2 – Distribution of patients with clinical stage T1c and Gleason scores 2-6, according to PSA levels.
PSA Levels N Patients N Events % Censorships
0 - 4.0 012  - 100.0%
4.1 - 10.0 121 15 087.6%
10.1 - 20.0 057 12 079.0%
> 20.0 016 05 068.8%
Figure 1  – Probability curve for recurrence-free survival according to PSA categories in patients with clinical stage T1c, and Gleason
scores 2 - 6.
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Table 3 –  Distribution of patients with clinical stage T1c and Gleason scores 7 - 8, according to PSA levels.
PSA  Levels N  Patients N  Events %  Censorship
0 - 4.0 05 0 100.0%
4.1 - 10.0 34 7 079.4%
10.1 - 20.0 10 6 040.0%
> 20.0 02 0 100.0%
chemical recurrence of disease according to PSA
categories for patients with clinical stage T1c,
Gleason scores 7 and 8 (Figure-2) show statistical
significance (p = 0.039), when comparing PSA lev-
els < 4 ng/mL, 4.1-10 ng/mL and 10.1-20 ng/mL.
Only 2 patients had Gleason 7-8 and PSA > 20 ng/
mL; however, they did not present recurrence of dis-
ease. These particular individuals had a follow-up of
19.5 months. Moreover, both specific individuals had
PSA values of 21 ng/mL and 23.5 ng/mL.
Finally, we constructed a graph (Figure-3)
which groups all individuals, regardless of Gleason
score, which is summarized in Table-4. In addition to
the absence of biochemical recurrence with PSA < 4
Figure 2 – Probability curve for recurrence-free survival according to PSA categories in patients with clinical stage T1c, and Gleason
scores 7 - 8.
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ng/mL, even after a median follow-up of 85.4
months, it is important to stress that, for individuals
with PSA 4.1 to 10.0 ng/mL after 89.1 months, the
probability of remaining free of biochemical recur-
rence is 65.1%. For patients with PSA of 10.1 to
20.0 ng/mL, after 92.6 months the probability of
being free of biochemical recurrence is 53.4%. Fi-
nally, in men with PSA > 20.0 ng/mL, the probabil-
ity of being free of biochemical recurrence is 72.2%;
however, in this particular group, we stress that the
Figure 3 – Probability curve for recurrence-free survival according to PSA categories in patients with clinical stage T1c, and Gleason
scores 2 - 8.
median follow-up was substantially shorter – only
19.5 months.
COMMENTS
The study demonstrated that the life expect-
ancy free of biochemical recurrence in individuals
with PCa clinical stage T1c and undergoing radical
prostatectomy is higher in those with PSA inferior
to 4.
Table 4 –  Distribution of patients with clinical stage T1c and Gleason scores 2 - 8, according to PSA levels.
PSA  Levels N  Patients N  Events %  Censorship
0 - 4.0   17   - 100.0%
4.1 - 10.0 155 22 085.8%
10.1 - 20.0   67 18 073.1%
> 20.0 018   5   72.2%
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From 1986 and 1999, the use of PSA for
screening has reduced the incidence of metastatic PCa
from 50 to 70% (11). Considered more lethal than
cardiac disease for between 60 and 80 year olds, the
PCa is currently diagnosed in its localized form in
86% of men (12). Additionally, pathological changes
of the prostate are identified during autopsies in 64%
of men aged between 60 and 70 years of age (13).
The assessment of PSA for screening PCa has
enabled an early diagnosis and treatment of the dis-
ease. This statement can be corroborated by one study,
which compared men with PCa clinical stage T1c and
PSA between 2.6 and 4 ng/mL, and individuals with
PSA between 4.1-10 ng/mL (5). The study demon-
strated that in the first group there are higher chances
of organ-confined disease and lower tumor volume.
Johansson et al. (14) showed that observa-
tion could be dangerous to men with a life expect-
ancy of over 10 years, demonstrating that after 15
years under a surveillance regimen the cancer-spe-
cific mortality increased from 15 to 44/1000, progres-
sion-free survival dropped from 45% to 36%, me-
tastasis-free survival decreased from 76.9% to 51.2%
and cancer-specific survival dropped from 78.7% to
54.4%. These figures confirm that a long follow-up
is required in PCa so that the benefits of early diag-
nosis and treatment can be observed. Additionally,
the probability of death due to disease progression
after 15-year surveillance increases from 4 to 30%
with Gleason scores of 2-6 and 42 to 87% for Gleason
scores of 7-10 (15).
In individuals under a surveillance regimen,
the need for treatment was confirmed in 57% and
73.2% after 2 and 4 years respectively, with an in-
crease in Gleason score in 24% of men after 3.8 years
(16).
It is possible that non-palpable prostate tu-
mors evidence significant disease, since this study
has revealed a 12.4% chance of biochemical recur-
rence in individuals with PSA from 4.1 to 10 ng/mL
and 21% when PSA are between 10.1 and 20 ng/mL,
in spite of stage T1c even in low risk tumors, with
Gleason scores of 2-6. On the other hand, when we
group all individuals regardless of Gleason score, the
expectancy of biochemical recurrence-free survival
remains at 100% when PSA < 4 ng/mL and decreases
drastically to 65.1 % and 53.4 % when the PSA is 4.1
- 10 and 10.1 - 20 ng/mL respectively.
When analyzing Figure-2, for PSA levels of
4.1-10 ng/mL and 10.1-20 ng/mL, it is important to
stress that the biochemical recurrence-free survival
drops from 79.4% to 40% when only the Gleason
score 7-8 is assessed, however it is 100% both in in-
dividuals with PSA lower than four and in the two
patients with PSA higher than 20 ng/mL. However,
when all individuals are grouped (both low and high
risk tumors as represented in Figure-3), the appar-
ently contradictory probability of biochemical recur-
rence occurring in 72.2% of men with PSA > 20 ng/
mL is broken down – especially if we observe that in
those particular cases the follow-up lasted only 19.5
months. Probably this percentage will decrease with
evolving follow-up.
The need for surveillance in men between the
fifth and the sixth decades of life should be consid-
ered. Some authors, by the way, advocate the perfor-
mance of prostate biopsy establishing a PSA value
up to 2.6 ng/mL as the upper normal limit (8) for men
aged less than 60 years of age (11).
Since the classical concept by Whitmore (17)
about the paradox existing in the treatment of PCa (is
cure required when it is possible, or is it possible when
it is required?), with the wide use of PSA in screen-
ing and the dramatic increase in the detection of or-
gan-confined disease, the concept of clinically sig-
nificant disease has become very important due to
the risk of over treating the PCa. The main studies
comparing radical prostatectomy with a surveillance
regimen have been initiated in order to answer these
questions. The Scandinavian prospective randomized
study (6) assessing the development of metastasis in
localized PCa has shown that metastases occurred in
13.4% and 27.3% for the surgery and the surveillance
regimen groups respectively; in the untreated group
the risk of metastases was 37% higher than in the
group undergoing surgery with a median follow-up
of 6 years. The risk of death after 8 years was 7.1%
and 13.6% for the surgery and the surveillance regi-
men groups respectively; after a 10-year follow-up
the risk of death increases to 16.8% in untreated men.
The concern to avoid over treatment in men
with PCa should be carefully considered, however,
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the majority of T1c tumors are already significant
tumors; that is, they present one of the following fea-
tures on biopsy: Gleason patter 4, = 3 positive frag-
ments on biopsy and a fragment more than 50% af-
fected by tumor (18). Carter et al. (19) obtained 31%
of progression of disease during the first year of sur-
veillance regimen in low risk tumors on the initial
biopsy; that is, absence of primary Gleason pattern
4/5, < 3 positive fragments /12, no fragment more
than 50% affected and PSA density of < 0.15).
With the possibility of over treating the PCa,
currently 25% of men undergoing radical prostatec-
tomy require a second therapy during the first 5 years
following surgery (20). This figure begs the question
of the correct PSA value that should be considered
normal for each individual.
In order to illustrate the great dilemma con-
cerning PCa screening, we need to evaluate the fol-
lowing situation: in Brazil, according to data from
the Ministry of Health in 2005, there are approxi-
mately 23 million men between 40 and 79 years old.
Among these men, and if we apply the worldwide
statistics to our country, approximately 92% of men
have PSA < 4 ng/mL. Of those 8% of individuals with
PSA > 4, we will find 25% or 500,000 men with PCa.
These figures are, to say the least, disturbing.
This study has some limitations, since it is
retrospective and the digital rectal examination can
be subjective. On the other hand, we considered as a
positive factor the fact that it as a homogeneous group
with follow-up longer than 7 years, which was as-
sessed and operated on by the same surgeon.
We must make every effort to understand the
natural history of prostate cancer, which is often un-
predictable, and try to find the best moment for indi-
cating prostate biopsy based on PSA.
CONCLUSION
With the acknowledgement of limitations in
accuracy for identifying men with small volume can-
cer prostate, the attitude of avoiding biopsy can de-
lay the diagnosis and result in losing the opportunity
to cure.
Adriana Sañudo performed the statistical analysis
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